文献速递呼吸衰竭与机械通气重症综合管理与镇静镇痛

重症COVID-19中度至重度ARDS患者吸入一氧化氮(iNO)治疗评估:多中心队列研究

Evaluation of inhaled nitric oxide (iNO) treatment for moderate-to-severe ARDS in critically ill patients with COVID-19: a multicenter cohort study.
PubMed 文献 · Crit Care · 2022-10-03
一句话结论重症COVID-19中重度ARDS患者中,iNO挽救治疗改善氧合但无死亡率获益,且与AKI、肺炎、住院时间延长和VFDs减少相关。

该多中心回顾性队列研究纳入2020年3月1日至2021年7月31日收治的确诊COVID-19重症成人患者,筛选1598例、纳入815例,按ICU期间是否使用iNO分为两组,倾向评分匹配(1:2)后210例进入分析。主要终点为iNO使用后24小时氧合参数改善,结果显示PaO2、FiO2需求、P/F比、氧合指数均显著改善,中位ICU入住6天后给药。但30天死亡率(HR 1.18;95%CI 0.77,1.82;p=0.45)和院内死亡率(HR 1.40;95%CI 0.94,2.11;p=0.10)两组相似,iNO组无呼吸机天数显著更少、ICU和住院时间显著更长,AKI(OR 2.35;95%CI 1.30,4.26;p=0.005)和医院/呼吸机获得性肺炎(OR 3.2;95%CI 1.76,5.83;p=0.001)风险更高。

要点

  • iNO使用后24小时氧合参数(PaO2、FiO2需求、P/F比、氧合指数)显著改善,给药中位时间为入ICU后6天。
  • 30天死亡率两组相似(HR 1.18;95%CI 0.77,1.82;p=0.45),院内死亡率亦相似(HR 1.40;95%CI 0.94,2.11;p=0.10)。
  • iNO组无呼吸机天数显著更少,ICU和住院时间显著更长。
  • iNO组AKI风险更高(OR 2.35;95%CI 1.30,4.26;p=0.005),医院/呼吸机获得性肺炎风险更高(OR 3.2;95%CI 1.76,5.83;p=0.001)。
  • 该研究为多中心回顾性队列,倾向评分匹配(1:2)后210例,提示iNO挽救治疗改善氧合但无生存获益。

适用人群与场景

  • 确诊COVID-19的重症成人患者,收治时间为2020年3月1日至2021年7月31日。
  • 符合中度至重度ARDS的纳入标准者,按ICU期间是否使用iNO分为两组。

研究设计与关键结果

  • 多中心回顾性队列研究,筛选1598例、纳入815例,倾向评分匹配(1:2)后210例进入分析。
  • 主要终点:iNO使用后24小时氧合参数(PaO2、FiO2需求、P/F比、氧合指数)显著改善,给药中位时间为入ICU后6天。
  • 30天死亡率两组相似(HR 1.18;95%CI 0.77,1.82;p=0.45),院内死亡率两组相似(HR 1.40;95%CI 0.94,2.11;p=0.10)。
  • iNO组无呼吸机天数显著更少,ICU和住院时间显著更长。
  • iNO组AKI风险更高(OR 2.35;95%CI 1.30,4.26;p=0.005),医院/呼吸机获得性肺炎风险更高(OR 3.2;95%CI 1.76,5.83;p=0.001)。

证据类型、等级与局限

  • 证据类型:多中心回顾性队列研究。
  • 局限:原文未报告局限性。

对床旁实践的改变

  • 对于重症COVID-19中度至重度ARDS患者,作者认为iNO挽救治疗与氧合参数改善相关,但无死亡率获益。
  • 作者认为iNO使用与AKI、肺炎风险更高、住院时间更长及无呼吸机天数更少相关。
  • 原文指出iNO被用作难治性低氧血症的挽救治疗,尽管有推荐反对使用该治疗。

提炼说明

  • 本条依据论文摘要整理;摘要未涉及「诊断标准与关键阈值」「处置流程与药物剂量」「红旗征与不能漏的情况」「指南或共识出处」,故未列出这些栏目;全文请点「阅读原文」。
英文原文(摘要)· 点击展开

BACKGROUND: Inhaled nitric oxide (iNO) is used as rescue therapy in patients with refractory hypoxemia due to severe COVID-19 acute respiratory distress syndrome (ARDS) despite the recommendation against the use of this treatment. To date, the effect of iNO on the clinical outcomes of critically ill COVID-19 patients with moderate-to-severe ARDS remains arguable. Therefore, this study aimed to evaluate the use of iNO in critically ill COVID-19 patients with moderate-to-severe ARDS.

METHODS: This multicenter, retrospective cohort study included critically ill adult patients with confirmed COVID-19 treated from March 01, 2020, until July 31, 2021. Eligible patients with moderate-to-severe ARDS were subsequently categorized into two groups based on inhaled nitric oxide (iNO) use throughout their ICU stay. The primary endpoint was the improvement in oxygenation parameters 24 h after iNO use. Other outcomes were considered secondary. Propensity score matching (1:2) was used based on the predefined criteria.

RESULTS: A total of 1598 patients were screened, and 815 were included based on the eligibility criteria. Among them, 210 patients were matched based on predefined criteria. Oxygenation parameters (PaO2, FiO2 requirement, P/F ratio, oxygenation index) were significantly improved 24 h after iNO administration within a median of six days of ICU admission. However, the risk of 30-day and in-hospital mortality were found to be similar between the two groups (HR: 1.18; 95% CI: 0.77, 1.82; p = 0.45 and HR: 1.40; 95% CI: 0.94, 2.11; p= 0.10, respectively). On the other hand, ventilator-free days (VFDs) were significantly fewer, and ICU and hospital LOS were significantly longer in the iNO group. In addition, patients who received iNO had higher odds of acute kidney injury (AKI) (OR (95% CI): 2.35 (1.30, 4.26), p value = 0.005) and hospital/ventilator-acquired pneumonia (OR (95% CI): 3.2 (1.76, 5.83), p value = 0.001).

CONCLUSION: In critically ill COVID-19 patients with moderate-to-severe ARDS, iNO rescue therapy is associated with improved oxygenation parameters but no mortality benefits. Moreover, iNO use is associated with higher odds of AKI, pneumonia, longer LOS, and fewer VFDs.

来源:Crit Care,查看原文。版权归原作者所有。

参考来源

  1. Al Sulaiman K, Korayem GB, Altebainawi AF, et al. Evaluation of inhaled nitric oxide (iNO) treatment for moderate-to-severe ARDS in critically ill patients with COVID-19: a multicenter cohort study. Crit Care. 2022. PMID: 36192801. doi:10.1186/s13054-022-04158-y

供执业医师抢救与诊疗参考,不替代临床判断;剂量请结合体重、肝肾功能和本院药品规格复核,以指南原文为准。